glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ( 1) 1 GLP-1 RAs 1 GLP-1 RAs 2 GLP-1 Receptor GLP-1 Receptor (GLP-1R) (pleiotropic effects) GLP-1 RAs GLP-1R GLP-1R : GLP-1R (-cells) GLP-1 (glucose-dependent insulinotropic action) : GLP-1R sinoatrial node 2 10 GLP-1 RAs : GLP-1R paraventricular nucleus arcuate nucleus hypothalamus, nucleus tractus solitarius area postrema : GLP-1R (natriuresis) (nephroprotection) : GLP-1R Brunners glands myenteric plexus macrophages T cells GLP-1RAs (atherosclerosis): GLP-1R atherosclerotic plaques GLP-1R macrophages macrophages foam cells : nitric oxide (NO) : GLP-1RAs atherosclerotic plaques Nuclear Factor-B (NF-B): Interleukin-6 (IL_6) Tumor Necrosis Factor-alpha (TNF- ) macrophage (macrophage polarization): macrophage M1 M2 : GLP-1R (tubular cells) podocyte ferroptosis: GLP-1 RAs ferroptosis ferroptosis : GLP-1 RAs Transforming growth factor-(TGF-) : (natriuresis) (hyperfiltration) GLP-1 RAs SGLT2 inhibitors GLP-1 RAs Sodium-glucose cotransporter-2 (SGLT-2) inhibitors LEADER: liraglutide MACE ( ) 13 22 15 SUSTAIN-6: semaglutide MACE 26 39 HARMONY Outcomes: albiglutide MACE 22 6 REWIND: dulaglutide (primary prevention) 31 dulaglutide MACE 12 (4 ) FLOW trial: semaglutide semaglutide 24 (eGFR) GLP-1 RAs LEADER HbA1c (urinary albumin-creatinine ratio

There is evidence to back up the efficiency of GLP-1 weight loss medication as an effective alternative
The itch comes from histamine activating sensory nerve endings in the dermis
Most patients experience peak nausea during the first 57 days after injection, with gradual improvement over 24 weeks
Many people report noticeable benefits within a few sessions, such as increased energy, clearer skin, and improved focus
A patient can finish a course of GLP-1 treatment significantly lighter and simultaneously in a weaker metabolic position than when they started if muscle preservation was not part of the plan. This is the mechanism behind what clinicians commonly observe in weight cycling